Early FDG PET in Melanoma
Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.
Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma
RADIATION: FDG PET/CT imaging
disease-free survival, 3 years
Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.